Established in 1845 and redesigned in October 2010, Scientific American remains the oldest continuously-published magazine in the United States. Written for leaders in business and technology, the outlet synthesizes science, technology and business into the clearest view of the future. Explores important ideas early, months and years before other media recognize their importance. Identifies and delivers the latest developments in biotechnology and information science, also with business-critical R&D across a broad range of fields. The magazine publishes 15 foreign language editions and has a total of more than 1,000,000 copies in circulation worldwide. Regular sections include Forum, which provides a platform for external experts to comment on science policy; Science Agenda, where editors can discuss different science issues; and Insights, which profiles a scientist or researcher and analyzes their contribution to society. Other sections include Anti Gravity and Skeptic. Regular columns include The Science of Health and TechnoFiles. Publicists should feel free to pitch anytime, although they should avoid pitching individual products or new company officer announcements. They should focus on science-based stories that are better told be a journalist than an expert. Email is always the preferred method for pitching. Writers should explain their idea and list the sources they plan to speak with. Also include one or two clips, or links to online writing samples. Editors try to respond in two to three weeks, but if you haven't heard back within a month feel free to follow up.

Established in 1899 and written for venture capitalists and hi-tech executives as an informational source on innovative and improved technologies and their applications. Focuses on promoting the understanding of emerging technologies and their impact. Strives to promote the understanding of emerging technology and its impact on the world. Aims to promote the understanding of emerging technologies and to analyze their commercial, social and political impacts. Assists technology and business leaders including CXOs, entrepreneurs, researchers, venture capitalists and financiers as they drive the global economy. Covers information technology, biotech, material science and nanotechnology. Features include new techniques, high-tech products, and market trends, as well as technology policy and it's relation to capital and market developments. Regular departments include Prototype (technologies in the pipeline), Innovation (biotech, nanotech, infotech), Upstream (hot technology of the month), Visualize (a featured technology and how it works), Insight (opinions, essays, reviews), Q&A (probes the minds of world-renowned innovators), Briefcase (case studies examining individual organizations), Reviews (books, articles, reports and products), Synopses (technological and scientific innovations) and Trailing Edge (lessons from innovations past). The outlet offers RSS (Really Simple Syndication) and a digital Podcast.

Endpoints News covers Biopharmaceutical industry. Offers the latest data-driven news and analysis for industry professionals covering research and development. Content is a combination of originally produced and curated from around the web and is available in real-time and via a daily newsletter. This site is available via RSS (Really Simple Syndication).

Impact Factor:22.66 (Source: Scimago Journal & Country Rank)Circulation: The figure is not currently disclosed.Aims of the journal:Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition it seeks to provide the highest-quality reviews and perspectives covering the entire field, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers and concise updates on the latest advances in fast-moving areas such as new drug approvals, patent law and emerging industry trends.Content: The journal covers the following subjects: Target discovery Rational drug design Combinatorial and parallel synthesis Medicinal chemistry Key compound classes Natural products High-throughput screening Novel therapeutic approaches to disease states Microarrays Bioinformatics and chemoinformatics Absorption, distribution, metabolism and elimination (ADME) Pharmacokinetics and pharmacodynamics Pharmacology Toxicology Pharmacogenomics and toxicogenomics Drug delivery Biopharmaceuticals Biotechnology Vaccines Clinical trial evaluation Regulatory issues PharmacoeconomicsEditorial contacts: See the list of editors here.The editorial office can be reached at naturereviews@nature.com.Manuscript submission:To be published in nature Reviews Drug Discovery a manuscript should meet the following criteria: Timely, accurate and balanced Important to scientists in the specific field Interesting and accessible to researchers in other areas of Drug DiscoverySubmit online at http://mts-nrdd.nature.com/cgi-bin/main.plex

BioCentury serves as the hub of several biotechnology publications, including BioCentury, the Bernstein Report on BioBusiness, BioCentury Extra, SciBX: Science-Business eXchange, BioCentury Week in Review and BioCentury Quarterly Stock Roundup. All content is original and created in-house using information from primary sources. The publication DOES NOT accept anything written by outside contributors (ie. contributed articles, white papers, etc.). Send press releases to the pressreleases@biocentury.com and longer pitches directly to Editors. This outlet offers RSS (Really Simple Syndication).